In this BPI Theater @ BIO presentation from Tuesday, 4 June 2019, Thomas Page, a vice president of engineering and asset development, explains how Fujifilm Diosynth partners with other organizations to deliver commercial-quality chemistry, manufacturing, and controls (CMC) for complex, next-generation biopharmaceuticals. Rather than simply transacting with clients, Page notes, his firm elects to go beyond standard engineering controls for patient safety and clinical filing. Using a wider array of risk assessments than is typical in the industry enables Fujifilm Diosynth to understand more completely its sponsor’s process requirements, budgetary constraints, business models, corporate culture, and fallback plans. The result is a fruitful, lasting, mutually beneficial partnership for next-generation therapy development.